HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .
Effects of oral raloxifene on serum estradiol levels and other markers of estrogenicity.
OBJECTIVE To determine the effects of raloxifene hydrochloride , 60 mg/d , on serum levels of E(2 ) , estrone , sex steroid-binding globulin , thyroxine-binding globulin , and follicle-stimulating hormone ( FSH ) in postmenopausal women . DESIGN R and omized placebo-controlled study at 16 centers in the United States . PATIENT(S ) Ninety three women 42 to 80 years of age who were at least 2 years postmenopausal . INTERVENTION(S ) Raloxifene ( n = 47 ) or placebo ( n = 46 ) for 3 months . MAIN OUTCOME MEASURE(S ) Levels of E(2 ) , estrone , sex steroid-binding globulin , thyroxine-binding globulin , and FSH were measured at baseline and after 3 months of therapy . RESULT ( S ) Raloxifene increased serum levels of sex steroid-binding globulin and thyroxine-binding globulin and decreased FSH levels compared with placebo . Levels of E(2 ) and estrone were unaffected . CONCLUSION ( S ) In postmenopausal women , raloxifene ( 60 mg/d ) did not increase serum estrogen levels ; however , it increased levels of sex steroid-binding globulin and thyroxine-binding globulin and decreased FSH levels
HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .